Parallel VMamba and Attention-Based Pneumonia Severity Prediction from CXRs: A Robust Model with Segmented Lung Replacement Augmentation.

Publication date: May 22, 2025

Background/Objectives: Rapid and accurate assessment of lung diseases, like pneumonia, is critical for effective clinical decision-making, particularly during pandemics when disease progression can be severe. Early diagnosis plays a crucial role in preventing complications, necessitating the development of fast and efficient AI-based models for automated severity assessment. Methods: In this study, we introduce a novel approach that leverages VMamba, a state-of-the-art vision model based on the VisualStateSpace (VSS) framework and 2D-Selective-Scan (SS2D) spatial scanning, to enhance lung severity prediction. Integrated in a parallel multi-image regions approach, VMamba effectively captures global and local contextual features through structured state-space modeling, improving feature representation and robustness in medical image analysis. Additionally, we integrate a segmented lung replacement augmentation strategy to enhance data diversity and improve model generalization. The proposed method is trained on the RALO and COVID-19 datasets and compared against state-of-the-art models. Results: Experimental results demonstrate that our approach achieves superior performance, outperforming existing techniques in prediction accuracy and robustness. Key evaluation metrics, including Mean Absolute Error (MAE) and Pearson Correlation (PC), confirm the model’s effectiveness, while the incorporation of segmented lung replacement augmentation further enhances adaptability to diverse lung conditions. Conclusions: These findings highlight the potential of our method for reliable and immediate clinical applications in lung infection assessment.

Open Access PDF

Concepts Keywords
Diagnostics automatic prediction
Efficient chest X-ray
Global data augmentation
Pc lung diseases
Pneumonia mamba
pneumonia
severity quantification

Semantics

Type Source Name
disease MESH Pneumonia
disease MESH lung diseases
disease MESH disease progression
disease IDO role
disease MESH complications
disease MESH COVID-19
disease MESH infection
disease IDO country
disease MESH morbidity
disease IDO process
disease MESH tuberculosis
pathway KEGG Tuberculosis
disease MESH stroke
disease MESH diabetic retinopathy
disease MESH COPD
drug DRUGBANK Hyaluronic acid
drug DRUGBANK Flunarizine
drug DRUGBANK Methacholine
drug DRUGBANK Aspartame
disease MESH clinical relevance
drug DRUGBANK Trestolone
disease MESH abnormalities
drug DRUGBANK Titanium
disease IDO intervention
disease MESH pleural effusion
disease MESH Uncertainty
disease MESH etiology
drug DRUGBANK Lauric Acid
disease MESH usual interstitial pneumonia
disease MESH interstitial lung disease
disease MESH macular edema
drug DRUGBANK Guanosine
disease IDO algorithm
drug DRUGBANK Coenzyme M

Original Article

(Visited 1 times, 1 visits today)